Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Radiation: Ablative Radiation TherapyOther: Standard of care
- Registration Number
- NCT03784755
- Lead Sponsor
- Canadian Cancer Trials Group
- Brief Summary
The purpose of this study is to compare the effects of ablative therapy (radiation or surgery) to all sites of disease combined with standard treatments on prostate cancer, compared to the standard or usual treatments used to treat this disease.
- Detailed Description
The standard or usual treatment for this disease is systemic therapy, which includes androgen deprivation therapy (ADT) with or without chemotherapy or hormone therapy. Additionally, for some patients with specific disease features, standard treatment may also include ablative treatment (radiation or surgery) of the prostate gland if this was not completed prior to enrolling into this study.
Ablative Therapy is a procedure used to destroy cancer cells and tissue. In this study Stereotactic Body Radiation Therapy (SBRT) or surgery will be used to destroy prostate cancer metastases. It is not clear if ablative therapy (SBRT or surgery) to all sites of disease used in combination with standard systemic therapy can offer better results than standard treatment alone.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Male
- Target Recruitment
- 409
- Histologic diagnosis/confirmation of prostate adenocarcinoma and no evidence of small cell cancer.
- Stage IV at presentation or relapse after curative intent therapy, classification per AJCC 8th edition: M1 disease with ≤ 5 metastases
- ≤ 3 metastases in any non-bone organ system
- Zoladex must commence within 12 weeks prior to randomization or within 12 weeks after randomization.
- Radiology (CT/MRI chest/abdomen/pelvis) within 42 days of randomization
- Bone scan within 42 days of randomization
- All tumours (Primary prostate and metastases) must be amenable to local ablative therapy (radiation and/or surgery).
- Age ≥ 18
- ECOG performance 0-2
- Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and economics questionnaires in either English or French
- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
- Patients must be medically suitable for study treatments as assessed by the appropriate specialties: medical, radiation, and surgical
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen
- Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
- In accordance with CCTG policy, ablative therapy to metastases is to begin within 6 weeks after patient randomization
- Men of childbearing potential must have agreed to use a highly effective contraceptive method to prevent pregnancy while on study
- Patient must consent to provision of, and Investigator must confirm location of and commit to obtain a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative studies described in the protocol may be conducted. Where tissue exists but local centre regulations prohibit submission of blocks of tumour tissue, the approval of the CCTG must be sought prior to randomization of the first patient to allow cores (two 2 mm cores of tumour from the block) and slides (20 x 5 micron thick unstained slides) of representative tumour tissue to be substituted
- Patient must consent to provision of samples of whole blood (for cfDNA) in order that the specific correlative studies described in the protocol may be conducted.
- Prior treatment with ADT in the neoadjuvant or adjuvant setting, unless treatment was discontinued ≥ 12 months prior to randomization AND total duration of treatment was ≤ 36 months (including expiry of last depot injection).
- Previously diagnosed recurrent/metastatic disease which has been already treated with any systemic therapy or radiotherapy with palliative intent.
- Castration resistant prostate cancer, defined as rising PSA (per PCWG3) or radiographic progression in the setting of castrate levels of serum testosterone (< 1.7 nmol/L).
- Patients who present with de novo stage IV disease with pelvic lymphadenopathy as their only site of metastases (N1 M0), where the primary prostate has never been treated with curative intent prostate surgery or radiotherapy in the past.
- Inability to treat all sites of disease with local ablative therapy
- Patients with parenchymal brain metastases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 2 (standard systemic therapy + ablative therapy)) Ablative Radiation Therapy Local Ablative therapy to all sites of disease (including untreated prostate primary) + Standard systemic therapy Arm 2 (standard systemic therapy + ablative therapy)) Standard of care Local Ablative therapy to all sites of disease (including untreated prostate primary) + Standard systemic therapy Arm 1 (standard of care) Standard of care Standard systemic therapy + Ablative therapy to untreated prostate primary for patients with low volume metastatic disease burden
- Primary Outcome Measures
Name Time Method Failure-free Survival 6 years defined as the time from randomization to the time of the first occurrence.
- Secondary Outcome Measures
Name Time Method Quality of Life measured by Bone Metastases module (BM22) 6 years The BM22 has 22 questions consisting of the 4 subscales (painful sites (PS) and pain characteristics (PC) on the symptom scale and functional interference (FI) and psychosocial aspects (PA) on the functional scale). Modules, relevant subscales will also be linear transformed to standardize the raw score to range between 0 and 100 in accordance with the EORTC scoring manuals.
Quality of Life measured by prostate (PR25) questionnaire module 6 years has 25 questions in four domains (urinary, bowel, sexual, and hormonal). Modules, relevant subscales will also be linear transformed to standardize the raw score to range between 0 and 100 in accordance with the EORTC scoring manuals.
Radiographic Progression-free Survival 6 years the comparison of these outcomes between the two treatment arms will be tested by the log-rank test
Incidence of new metastases as first event 6 years the comparison of these outcomes between the two treatment arms will be tested by the log-rank test
Ablative treatment related adverse events (>/= grade 3) using CTCAE v5.0 6 years Economic analysis measured by EQ-5D-5L 6 years The robustness of the model results will be assessed using one-way and multi-way sensitivity analyses. Major drivers of medical care costs, namely hospitalization, chemotherapy and survival, will be varied ± 20%, to examine the impact on the base-case incremental cost effectiveness ratios (ICERs). Bootstrapping and the development of a cost-effectiveness acceptability curve will also be conducted.
Quality of Life measured by EORTC QLQ-C30 6 years It consists of both multi-item scales and single item measures, including five functioning domains, a global quality of life domain, three symptom domains and six single items. For each domain or single item measure a linear transformation will be applied to standardize the raw score to range between 0 and 100
Economic analysis by determining an incremental cost-effectiveness ratio reported as a difference in cost per FFS-year between the 2 arms 6 years Overall Survival 6 years the comparison of these outcomes between the two treatment arms will be tested by the log-rank test
Trial Locations
- Locations (18)
BCCA - Victoria
🇨🇦Victoria, British Columbia, Canada
CancerCare Manitoba
🇨🇦Winnipeg, Manitoba, Canada
QEII Health Sciences Centre
🇨🇦Halifax, Nova Scotia, Canada
Royal Victoria Regional Health Centre
🇨🇦Barrie, Ontario, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
🇨🇦Hamilton, Ontario, Canada
Kingston Health Sciences Centre
🇨🇦Kingston, Ontario, Canada
Trillium Health Partners - Credit Valley Hospital
🇨🇦Mississauga, Ontario, Canada
Ottawa Hospital Research Institute
🇨🇦Ottawa, Ontario, Canada
Algoma District Cancer Program
🇨🇦Sault Ste. Marie, Ontario, Canada
Odette Cancer Centre
🇨🇦Toronto, Ontario, Canada
CIUSSS de l'Est-de-I'lle-de-Montreal
🇨🇦Montreal, Quebec, Canada
Health Sciences North
🇨🇦Sudbury, Ontario, Canada
University Health Network
🇨🇦Toronto, Ontario, Canada
CHUM-Centre Hospitalier de l'Universite de Montreal
🇨🇦Montreal, Quebec, Canada
The Jewish General Hospital
🇨🇦Montreal, Quebec, Canada
Hotel-Dieu de Quebec
🇨🇦Quebec City, Quebec, Canada
Allan Blair Cancer Centre
🇨🇦Regina, Saskatchewan, Canada
Saskatoon Cancer Centre
🇨🇦Saskatoon, Saskatchewan, Canada